TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16890064

Group type: EXPERIMENTAL
Intervention: Morphine PCA
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Morphine Ondansetron PCA
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo PCA
Number of subjects: 120
Study: 14693593

Group type: EXPERIMENTAL
Intervention: 2-chloroprocaine with fentanyl (20 micro g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 2-chloroprocaine with saline (control)
Number of subjects: 8
Study: 11527621

Group type: EXPERIMENTAL
Intervention: Mild renal insufficiency (creatinine 1.2 mg/dl to 1.4 mg/dl)
Number of subjects: 2763

Group type: EXPERIMENTAL
Intervention: Moderate renal insufficiency (creatinine >1.4 mg/dl)
Number of subjects: 2763

Group type: COMPARATOR
Intervention: Normal renal function (creatinine < 1.2 mg/dl)
Number of subjects: 2763
Study: 9000046

Group type: EXPERIMENTAL
Intervention: Nonpharmacological treatment for CFS
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CFS patients
Number of subjects: 43
Study: 8515355

Group type: EXPERIMENTAL
Intervention: Moderate and strenuous exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 3727591

Group type: EXPERIMENTAL
Intervention: 13% maltodextrin solution (52 kcal, 160 mOsm/l)
Number of subjects: 200

Group type: COMPARATOR
Intervention: fully adapted formula (67 kcal/dl)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: both groups (A and B)
Number of subjects: 200
Study: 31520727

Group type: EXPERIMENTAL
Intervention: ACP Communication Assessment Tool (ACP-CAT)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ACP-CAT total scores
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall impression of ACP communication skills
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Overall ability to respond to emotion
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: ACP-CAT
Number of subjects: 29
Study: 29234931

Group type: EXPERIMENTAL
Intervention: ACCESS Program (group intervention)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 44
Study: 26762368

Group type: EXPERIMENTAL
Intervention: Jejunal feeding
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 12
Study: 24696417

Group type: EXPERIMENTAL
Intervention: Urinary angiogenin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Urinary clusterin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Voided urine cytology
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined use of voided urine cytology with angiogenin and clusterin
Number of subjects: 90
Study: 23644911

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 21122199

Group type: EXPERIMENTAL
Intervention: AutoPulse
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard manual external chest compression
Number of subjects: 85
Study: 19025038

Group type: EXPERIMENTAL
Intervention: Structured intervention program of listening skills in quiet and in noise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with no special treatment
Number of subjects: 20
Study: 16164385

Group type: EXPERIMENTAL
Intervention: Lower increase in HIV-related health symptoms
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Satisfaction with social support
Number of subjects: 65
Study: 12521598

Group type: EXPERIMENTAL
Intervention: Topical alpha-tocotrienol (5% w/vol)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vehicle-only control
Number of subjects: 11

Group type: COMPARATOR
Intervention: Benzoyl peroxide (10%)
Number of subjects: 11
Study: 10227567

Group type: EXPERIMENTAL
Intervention: Framingham Study risk estimates for coronary heart disease events
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dundee Risk Disk and PROCAM Study estimates
Number of subjects: 0
Study: 8713558

Group type: EXPERIMENTAL
Intervention: 0.5 mg alfuzosin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 1 mg alfuzosin
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 2 mg alfuzosin
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 1854053

Group type: EXPERIMENTAL
Intervention: Additional dose of propofol (0.7 mg.kg‐1) in group P2
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard dose of propofol (1.5 mg.kg‐1) in group P1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (P1 and P2)
Number of subjects: 50
Study: 6140883

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29547939

Group type: EXPERIMENTAL
Intervention: Balloon kyphoplasty
Number of subjects: 354
Study: 28913717

Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools (ADAPT)
Number of subjects: 336

Group type: COMPARATOR
Intervention: web and print resources-as-usual
Number of subjects: 336
Study: 27100401

Group type: EXPERIMENTAL
Intervention: BpTRU device
Number of subjects: 62

Group type: COMPARATOR
Intervention: WatchBP Office monitor
Number of subjects: 62
Study: 25180056

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Melatonin 2 mg twice per day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Melatonin 4 mg twice per day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Melatonin 8 mg twice per day
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study: 21965229

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MFX)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Nonstandardised antibiotic therapy (control)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: β-lactam plus macrolide combination (BLM)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Both MFX and BLM
Number of subjects: 1236
Study: 19171612

Group type: EXPERIMENTAL
Intervention: Thimerosal exposure (62.5 microg)
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Thimerosal exposure (137.5 microg)
Number of subjects: 1403

Group type: COMPARATOR
Intervention: Control group (no specific thimerosal exposure mentioned)
Number of subjects: 1403
Study: 17094530

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam (1 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg)
Number of subjects: 0
Study: 15274256

Group type: EXPERIMENTAL
Intervention: A-V Impulse System foot pump
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 200
Study: 11321236

Group type: EXPERIMENTAL
Intervention: GM-CSF (80 microg or 250 microg) administered as a single injection with the first and second doses of hepatitis B vaccine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine administered at 0, 1, and 6 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Naïve T-helper cells (CD4+CD45RA+)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Elderly who responded to HBV vs those who did not
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Age and percent naive CD4 T cells
Number of subjects: 45
Study: 9598220

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 36
Study: 7874712

Group type: EXPERIMENTAL
Intervention: 7F guiding catheters
Number of subjects: 115

Group type: COMPARATOR
Intervention: 8F guiding catheters
Number of subjects: 115
Study: 3137632

Group type: EXPERIMENTAL
Intervention: 5-methoxypsoralen (40 mg daily at 9 p.m.)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31820602

Group type: EXPERIMENTAL
Intervention: Acupuncture at 'three points of iliolumbar' combined with celecoxib (200 mg once a day for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib alone (200 mg once a day for 3 days)
Number of subjects: 60
Study: 28535791

Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (ERT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (MorCAP untreated population)
Number of subjects: 32
Study: 24992652

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 23436915

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 12 months
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment for 24 months
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo treatment for 12 months
Number of subjects: 46
Study: 21472815

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone gel
Number of subjects: 458
Study: 18959591

Group type: EXPERIMENTAL
Intervention: Hydro-alcoholic solution of a phytocompound (20 gtt 30 min before meals for 2 weeks)
Number of subjects: 24
Study: 14691428

Group type: EXPERIMENTAL
Intervention: Supervised exercise program at ventilatory threshold (VT) for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48
Study: 12043864

Group type: EXPERIMENTAL
Intervention: ProFile Ni‐Ti.06 taper Series 29
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ProFile GT rotary instrumentation techniques
Number of subjects: 10
Study: 9821653

Group type: EXPERIMENTAL
Intervention: Conventional capsules in humans
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteric coated tablets in humans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional capsules in dogs (pentagastrin pretreated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional capsules in dogs (saline pretreated)
Number of subjects: 0
Study: 7666816

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol patch (50 micrograms daily) + levonorgestrel-releasing IUD (20 micrograms daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral therapy (2 mg of estradiol + 1 mg of noretisterone acetate daily)
Number of subjects: 40
Study: 2757882

Group type: EXPERIMENTAL
Intervention: Sustained release acetazolamide (SRA) 500 mg once or twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional acetazolamide (CA) 500 mg once or twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sustained release acetazolamide (SRA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional acetazolamide (CA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 772394

Group type: EXPERIMENTAL
Intervention: Mesterolone (2 mg/kg orally for 6 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no androgens)
Number of subjects: 45
Study: 30272630

Group type: EXPERIMENTAL
Intervention: Eviplera (TDF/FTC/RPV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Atripla (TDF/FTC/EFV)
Number of subjects: 48
Study: 29926644

Group type: EXPERIMENTAL
Intervention: Core strength training (n=8)
Number of subjects: 16
Study: 24661263

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Cognitive-Behavioral Therapy (CBT)
Number of subjects: 196
Study: 23257153

Group type: EXPERIMENTAL
Intervention: Telephonic interview
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Choice arm
Number of subjects: 521

Group type: COMPARATOR
Intervention: Mail
Number of subjects: 521

Group type: COMPARATOR
Intervention: Online
Number of subjects: 521
Study: 21753776

Group type: EXPERIMENTAL
Intervention: Lactotripeptides (LTPs) at 3 mg per day for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 19005687

Group type: EXPERIMENTAL
Intervention: 1.0 g ginger daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 2.0 g ginger daily
Number of subjects: 162

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Ginger (both dosages)
Number of subjects: 162
Study: 16849757

Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 2,475 mg/m2 per day for 7 days, repeated every 21 days.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 3,300 mg/m2 per day (highest dose tested).
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 1,050 mg/m2.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 1,860 mg/m2.
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Oral fenretinide at 2,475 mg/m2.
Number of subjects: 54
Study: 15619182

Group type: EXPERIMENTAL
Intervention: Care management (166 participants)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group (165 participants)
Number of subjects: 331
Study: 11735076

Group type: EXPERIMENTAL
Intervention: Group intervention for battered women
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 33
Study: 9221964

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg; 2g/kg and then 1 g/kg every three weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (IFN‐alpha; 3 MU/m2 subcutaneously three times weekly)
Number of subjects: 20
Study: 8214548

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline and pethidine
Number of subjects: 50
Study: 2886534

Group type: EXPERIMENTAL
Intervention: Single dose iv mezlocillin (5.0 g)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Three doses of iv cefuroxime plus metronidazole
Number of subjects: 116
Study: 28616797

Group type: EXPERIMENTAL
Intervention: Bimatoprost/timolol maleate fixed combination (BTFC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol maleate fixed combination (LTFC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Travoprost/timolol maleate fixed combination (TTFC)
Number of subjects: 50
Study: 27061696

Group type: EXPERIMENTAL
Intervention: Return-to-work coordinator (RTWC) model of care
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual hospital standard care (Control)
Number of subjects: 160
Study: 25008885

Group type: EXPERIMENTAL
Intervention: Sildenafil [1 mg/(kg . d)] three times daily for 7‐10 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment (Control group)
Number of subjects: 50
Study: 21822734

Group type: EXPERIMENTAL
Intervention: Fluency performance
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Decoding performance
Number of subjects: 153
Study: 20569928

Group type: EXPERIMENTAL
Intervention: Copper glycinate (2 mg copper/day) for 8 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 18164461

Group type: EXPERIMENTAL
Intervention: McKenzie method
Number of subjects: 0
Study: 16351509

Group type: EXPERIMENTAL
Intervention: High-isoflavone soy diet (113-207 mg/day total isoflavones)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low-isoflavone soy diet (<5 mg/day total isoflavones)
Number of subjects: 8
Study: 12351534

Group type: EXPERIMENTAL
Intervention: 150 mg Org 31710
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 10196730

Group type: EXPERIMENTAL
Intervention: Same-sex Stranger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Same-sex Best Friend
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alone
Number of subjects: 0
Study: 8522409

Group type: EXPERIMENTAL
Intervention: captopril 25 mg three times daily
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: xamoterol 200 mg twice daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 70
Study: 1971872

Group type: EXPERIMENTAL
Intervention: Gastric delivery system (GDS) for iron supplementation, 50 mg daily
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional ferrous sulphate, 50 mg daily
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gastric delivery system (GDS)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 722473

Group type: EXPERIMENTAL
Intervention: Phenobarbital (tranquilizer condition)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine (amphetamine condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk powder (placebo condition)
Number of subjects: 0
Study: 31589645

Group type: EXPERIMENTAL
Intervention: Potassium iodide capsule (225 μg iodine) daily for 26 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Iodized salt weekly for 26 weeks
Number of subjects: 106
Study: 28925046

Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (AEHS) 250 mg/kg and simvastatin 10 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aqueous extract of Hibiscus sabdariffa (AEHS) 500 mg/kg and simvastatin 20 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aqueous beverage of Hibiscus sabdariffa (ABHS) with single-dose simvastatin 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 0
Study: 26281572

Group type: EXPERIMENTAL
Intervention: Fangfeng Tongsheng granule (3 g, twice a day for 14 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo control (simulated agent granules, 3 g, twice a day for 14 days)
Number of subjects: 108
Study: 23858000

Group type: EXPERIMENTAL
Intervention: Tolvaptan (intervention group)
Number of subjects: 4133

Group type: EXPERIMENTAL
Intervention: Low body temperature group (<36 °C)
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4133
Study: 21681103

Group type: EXPERIMENTAL
Intervention: 17.5 mg transdermal nicotine (TDN) patch
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (drug‐free bandage)
Number of subjects: 40
Study: 19795771

Group type: EXPERIMENTAL
Intervention: NTG group (nitroglycerin-induced hypotension)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 16396863

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.89 mg/kg over 10 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 70
Study: 15293485

Group type: EXPERIMENTAL
Intervention: Task-orientated intervention (10 functional tasks for lower extremities, 3 times a week for 6 weeks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control intervention (practice of upper extremity activities, 3 times a week for 6 weeks)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Task-orientated intervention
Number of subjects: 91
Study: 11507005

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) following V(1) receptor blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study: 10987239

Group type: EXPERIMENTAL
Intervention: Liposuction (LS) combined with Controlled Compression Therapy (CCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled Compression Therapy (CCT) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liposuction (LS) + CCT
Number of subjects: 0
Study: 8526697

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 2114

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 2114
Study: 1294490

Group type: EXPERIMENTAL
Intervention: Sugar-fortified milk formula
Number of subjects: 110
Study: 6325044

Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg iv)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no ketanserin)
Number of subjects: 8
Study: 28828697

Group type: EXPERIMENTAL
Intervention: Metacognitive training (MCT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Occupational therapy (OT)
Number of subjects: 50
Study: 25040706

Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Post-partum women
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study: 25203881

Group type: EXPERIMENTAL
Intervention: Low Residue Diet (LRD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Clear Fluid (CF)
Number of subjects: 111
Study: 22157367

Group type: EXPERIMENTAL
Intervention: Erlotinib 150 mg daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vinorelbine 60 mg/m on days 1 and 8 every 3 weeks
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR-mutated patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vinorelbine (EGFR-mutated patients)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR wild type)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Vinorelbine (EGFR wild type)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Erlotinib and Vinorelbine (EGFR-mutated vs wild type)
Number of subjects: 113
Study: 19944151

Group type: EXPERIMENTAL
Intervention: 1 x 10(8)TCID(50) IMVAMUNE dose
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All three IMVAMUNE doses
Number of subjects: 164
Study: 18074075

Group type: EXPERIMENTAL
Intervention: Interferon beta products (Betaferon, Avonex, or Rebif)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 94
Study: 16256861

Group type: EXPERIMENTAL
Intervention: GM-CSF (10 microg/kg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: GM-CSF
Number of subjects: 14
Study: 11904617

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral iron sulfate
Number of subjects: 50
Study: 10208785

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 154

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 154
Study: 7603271

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation with social reinforcement (VR + SR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation without social reinforcement (VR - SR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: General range of motion exercises with social reinforcement (ROM + SR)
Number of subjects: 24
Study: 2152594

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 200 IU plus calcium 500 mg daily for 2 years
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin for 1 year
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (19 age-matched women, no treatment)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Withdrawal of calcitonin treatment for 1 year
Number of subjects: 26
Study: 31215777

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risedronate
Number of subjects: 0